182 related articles for article (PubMed ID: 36105365)
1. RBM8A Depletion Decreases the Cisplatin Resistance and Represses the Proliferation and Metastasis of Breast Cancer Cells via AKT/mTOR Pathway.
Song T; Zhang H
Breast J; 2022; 2022():4576789. PubMed ID: 36105365
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway.
Lu PW; Li L; Wang F; Gu YT
J Cell Physiol; 2019 Feb; 234(2):1904-1912. PubMed ID: 30145819
[TBL] [Abstract][Full Text] [Related]
3. Gigantol inhibits proliferation and enhances DDP-induced apoptosis in breast-cancer cells by downregulating the PI3K/Akt/mTOR signaling pathway.
Huang J; Liu C; Duan S; Lin J; Luo Y; Tao S; Xing S; Zhang X; Du H; Wang H; Huang C; Wei G
Life Sci; 2021 Jun; 274():119354. PubMed ID: 33737087
[TBL] [Abstract][Full Text] [Related]
4. Effects of endoplasmic reticulum stress on the autophagy, apoptosis, and chemotherapy resistance of human breast cancer cells by regulating the PI3K/AKT/mTOR signaling pathway.
Zhong JT; Yu J; Wang HJ; Shi Y; Zhao TS; He BX; Qiao B; Feng ZW
Tumour Biol; 2017 May; 39(5):1010428317697562. PubMed ID: 28459209
[TBL] [Abstract][Full Text] [Related]
5. Andrographolide Exhibits Anticancer Activity against Breast Cancer Cells (MCF-7 and MDA-MB-231 Cells) through Suppressing Cell Proliferation and Inducing Cell Apoptosis via Inactivation of ER-α Receptor and PI3K/AKT/mTOR Signaling.
Tohkayomatee R; Reabroi S; Tungmunnithum D; Parichatikanond W; Pinthong D
Molecules; 2022 May; 27(11):. PubMed ID: 35684480
[TBL] [Abstract][Full Text] [Related]
6. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
7. LHX6 inhibits the proliferation, invasion and migration of breast cancer cells by modulating the PI3K/Akt/mTOR signaling pathway.
Bi QJ; Men XJ; Han R; Li GL
Eur Rev Med Pharmacol Sci; 2018 May; 22(10):3067-3073. PubMed ID: 29863252
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting L1CAM Reverses Cisplatin Resistance of Triple Negative Breast Cancer Cells by Blocking AKT Signaling Pathway.
Zhang LY; Shen ZX; Guo L
Cancer Invest; 2022 Apr; 40(4):313-324. PubMed ID: 35040385
[TBL] [Abstract][Full Text] [Related]
9. FBXL16 modulates the proliferation and autophagy in breast cancer cells via activating SRC-3-AKT signaling pathway.
Yang M; Jing F
Reprod Biol; 2021 Sep; 21(3):100538. PubMed ID: 34333223
[TBL] [Abstract][Full Text] [Related]
10. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
Shi H; Pu J; Zhou XL; Ning YY; Bai C
Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of cannabinoid receptor 2 is associated with human breast cancer proliferation, apoptosis, chemosensitivity and prognosis via the PI3K/Akt/mTOR signaling pathway.
Song Q; Zhang W; Shi D; Zhang Z; Zhao Q; Wang M; Huang M; Meng J; Cui W; Luo X
Cancer Med; 2023 Jun; 12(12):13538-13550. PubMed ID: 37220224
[TBL] [Abstract][Full Text] [Related]
12. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
13. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1.
Yi D; Xu L; Wang R; Lu X; Sang J
Cell Biol Int; 2019 Jan; 43(1):12-21. PubMed ID: 30444043
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.
Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H
Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364
[TBL] [Abstract][Full Text] [Related]
15. Synergistic actions of Alpelisib and Melatonin in breast cancer cell lines with PIK3CA gene mutation.
de Godoy BLV; Moschetta-Pinheiro MG; Chuffa LGA; Pondé NF; Reiter RJ; Colombo J; Zuccari DAPC
Life Sci; 2023 Jul; 324():121708. PubMed ID: 37086897
[TBL] [Abstract][Full Text] [Related]
16. Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN/PI3K/AKT/mTOR signaling pathway.
Dastmalchi N; Hosseinpourfeizi MA; Khojasteh SMB; Baradaran B; Safaralizadeh R
Life Sci; 2020 Oct; 259():118239. PubMed ID: 32784058
[TBL] [Abstract][Full Text] [Related]
17. The cancer-testis antigen a-kinase anchor protein 3 facilitates breast cancer progression via activation of the PTEN/PI3K/AKT/mTOR signaling.
Zhan CH; Ding DS; Zhang W; Wang HL; Mao ZY; Liu GJ
Bioengineered; 2022 Apr; 13(4):8478-8489. PubMed ID: 35322748
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA -383-5p restrains the proliferation and migration of breast cancer cells and promotes apoptosis via inhibition of PD-L1.
Azarbarzin S; Hosseinpour-Feizi MA; Banan Khojasteh SM; Baradaran B; Safaralizadeh R
Life Sci; 2021 Feb; 267():118939. PubMed ID: 33359245
[TBL] [Abstract][Full Text] [Related]
19. MEDAG enhances breast cancer progression and reduces epirubicin sensitivity through the AKT/AMPK/mTOR pathway.
Li Z; Li C; Wu Q; Tu Y; Wang C; Yu X; Li B; Wang Z; Sun S; Sun S
Cell Death Dis; 2021 Jan; 12(1):97. PubMed ID: 33462219
[TBL] [Abstract][Full Text] [Related]
20. LINC00092 Modulates Oxidative Stress and Glycolysis of Breast Cancer Cells via Pyruvate Carboxylase-Mediated AKT/mTOR Pathway.
Chen W; Liu Y; Kang S; Lv X; Fu W; Zhang J; Song C
Oxid Med Cell Longev; 2022; 2022():5215748. PubMed ID: 35799892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
